Newsletter Signup | Join Community
Lynparza is an effective treatment for women with newly diagnosed and recurrent BRCA + and other mutated ovarian cancers
Avastin delays progression of advanced ovarian cancer but does not appear to prolong survival.
Combination of novel precision cancer medicines represents future direction of ovarian cancer treatment.
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
There is no longer a “one-size-fits-all” approach to ovarian cancer treatment update on precision cancer medicines.
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…